Skip to main content

Advertisement

Log in

Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature

  • Psoriasis (J Wu, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To highlight the most recent findings regarding the efficacy and safety of tildrakizumab in the treatment of chronic plaque psoriasis.

Recent Findings

Recent clinical trials have shown tildrakizumab to be more efficacious than placebo or etanercept. There are no head-to-head trials directly comparing tildrakizumab to any IL-23 p19, IL-17, or IL-17R inhibitor. Common adverse effects included headache, upper respiratory infection, nasopharyngitis, and cough.

Summary

Since tildrakizumab is a new biologic, there is currently a paucity of available evidence evaluating tildrakizumab in a comparative manor with respect to other biologic therapies. Tildrakizumab may be a useful addition in the armamentarium of available therapies, especially for patients who have failed other agents. Additional head-to-head trials are needed to better assess the comparative efficacy of tildrakizumab in relation to other biologic therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. Am J Prev Med. 2014;47(1):37–45. https://doi.org/10.1016/j.amepre.2014.02.012.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Bradham DD, Exum ML, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997;37(4):564–9.

    Article  CAS  Google Scholar 

  3. Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. https://doi.org/10.1590/abd1806-4841.20153038.

    Article  PubMed  Google Scholar 

  4. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50. https://doi.org/10.1016/j.jaad.2008.02.039.

    Article  PubMed  Google Scholar 

  5. Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13–23. https://doi.org/10.1016/j.det.2014.09.002.

    Article  CAS  PubMed  Google Scholar 

  6. Yang EJ, Beck KM, Liao W. Tildrakizumab-asmn: what’s in a name? Am J Clin Dermatol. 2018;19(3):291–2. https://doi.org/10.1007/s40257-018-0357-6.

    Article  PubMed  Google Scholar 

  7. • Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–34. https://doi.org/10.1080/1744666X.2017.1292137 This publication is important because it supports the use and development of an IL-23 p19 subunit–specific treatment versus the less precise IL-12/IL-23 p40 subunit inhibition seen with ustekinumab.

    Article  CAS  PubMed  Google Scholar 

  8. • Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616–26. https://doi.org/10.1111/jdv.14433 The reference clarifies how the IL-23/T H 17 immune axis is responsible for the development of psoriasis, and in understanding this link, biologics such as tildrakizumab have been created to help disrupt this axis and help patients.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998;111(6):1053–7.

    Article  CAS  Google Scholar 

  10. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–25.

    Article  CAS  Google Scholar 

  11. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–30.

    Article  CAS  Google Scholar 

  12. Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11–27. https://doi.org/10.1007/s00281-015-0539-8.

    Article  CAS  PubMed  Google Scholar 

  13. Nakajima K, Kanda T, Takaishi M, Shiga T, Miyoshi K, Nakajima H, et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol. 2011;186(7):4481–9. https://doi.org/10.4049/jimmunol.1000148.

    Article  CAS  PubMed  Google Scholar 

  14. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174–81. https://doi.org/10.1016/j.it.2012.11.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9(6):461–7.

    Article  CAS  Google Scholar 

  16. Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol. 2010;185(10):5688–91. https://doi.org/10.4049/jimmunol.1001538.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Howell ST, Cardwell LA, Feldman SR. Treating moderate-to-severe plaque psoriasis with guselkumab: a review of phase II and phase III trials. Ann Pharmacother. 2018;52(4):380–7. https://doi.org/10.1177/1060028017743268.

    Article  CAS  PubMed  Google Scholar 

  18. Levin AA, Gottlieb AB. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol. 2014;70(3):555–61. https://doi.org/10.1016/j.jaad.2013.10.043.

    Article  CAS  PubMed  Google Scholar 

  19. Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521(7551):222–6. https://doi.org/10.1038/nature14175.

    Article  CAS  PubMed  Google Scholar 

  20. • Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–88. https://doi.org/10.1016/S0140-6736(17)31279-5 This research publication conveys that phase 3 clinical trial data is essential to achieve FDA approval for tildrakizumab. With this publication, we learned that tildrakizumab is safe and effective in patients with moderate-to-severe chronic plaque psoriasis and that it is better than placebo and etanercept.

    Article  CAS  PubMed  Google Scholar 

  21. Tildrakizumab US prescribing information. 2018 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Accessed 24 Oct 2018.

  22. Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–9. https://doi.org/10.1111/bjd.13932.

    Article  CAS  PubMed  Google Scholar 

  23. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–74. https://doi.org/10.1016/S0140-6736(08)60725-4.

    Article  CAS  PubMed  Google Scholar 

  24. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84. https://doi.org/10.1016/S0140-6736(08)60726-6.

    Article  CAS  PubMed  Google Scholar 

  25. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17. https://doi.org/10.1016/j.jaad.2016.11.041.

    Article  CAS  PubMed  Google Scholar 

  26. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31. https://doi.org/10.1016/j.jaad.2016.11.042.

    Article  CAS  PubMed  Google Scholar 

  27. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61. https://doi.org/10.1016/S0140-6736(18)31713-6.

    Article  CAS  PubMed  Google Scholar 

  28. Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal phase 3 psoriasis studies. Abbvie: News Center Website. https://news.abbvie.com/news/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantly-greater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies.htm Published October 26, 2017. Accessed 11 Nov 2018.

  29. Risankizumab meets all primary endpoints reporting positive results in fourth pivotal phase 3 psoriasis study. Abbvie: News Center Website. https://news.abbvie.com/news/risankizumab-meets-all-primary-endpoints-reporting-positive-results-in-fourth-pivotal-phase-3-psoriasis-study.htm Published December 4, 2017. Accessed 11 Nov 2018.

  30. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38. https://doi.org/10.1056/NEJMoa1314258.

    Article  CAS  PubMed  Google Scholar 

  31. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56. https://doi.org/10.1056/NEJMoa1512711.

    Article  CAS  PubMed  Google Scholar 

  32. Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–86. https://doi.org/10.1111/bjd.14493.

    Article  CAS  PubMed  Google Scholar 

  33. Blauvelt A, Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77(2):372–4. https://doi.org/10.1016/j.jaad.2017.03.026.

    Article  PubMed  Google Scholar 

Download references

Funding

Kory P. Schrom is supported by a fellowship grant from the National Psoriasis Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kory P. Schrom.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Psoriasis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schrom, K.P., Bitterman, A. & Korman, N.J. Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature. Curr Derm Rep 8, 6–13 (2019). https://doi.org/10.1007/s13671-019-0251-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-019-0251-3

Keywords

Navigation